Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden

Social Science and Medicine

Volumn 124, Issue , 2015, Pages 39-47

  Ferrario, Alessandra ^a   Kanavos, Panos ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Access to medicines; Belgium; England; High cost medicines; Managed entry agreements; Netherlands; Risk sharing agreements; Sweden

Indexed keywords

COMMODITY PRICE; COST ANALYSIS; GOVERNANCE APPROACH; MEDICINE; PRICE DYNAMICS;

ARTICLE; BELGIUM; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; DRUG USE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MANAGED ENTRY AGREEMENT; MEDICATION COMPLIANCE; NETHERLANDS; PARTICIPATORY MANAGEMENT; REIMBURSEMENT; SWEDEN; UNCERTAINTY; UNITED KINGDOM; DRUG INDUSTRY; EUROPE; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; PROCEDURES; PUBLIC HEALTH; STANDARDS;

BELGIUM; ENGLAND; NETHERLANDS; SWEDEN; UNITED KINGDOM;

DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; NATIONAL HEALTH PROGRAMS;

EID: 84910654404     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.11.003     Document Type: Article

References (51)

1. Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv. Res. 2010, 10(153).
2. Arnberg K. The Ability of CED to Address Uncertainties and Improve Performance in Drug Use 14 February 2014, Presentation at the LSE Summit on risk sharing and managed entry agreements, London, UK.
3. Barros P.P. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ. 2011, 20(4):461-470.
4. Carbonneil C., Quentin F., Lee-Robin S.H., European Network Hlth Technol, A Acommon policy framework for evidence generation on promising health technologies. Int. J. Technol. Assess. Health Care 2009, 25(Suppl.2):56-67.
5. Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010, 96(3):179-190.
6. Casado B., Ruiz S., Genenz K., Schmidt F. Nuevas tendencias en la evaluación y financiación de medicamentos en Europa: Estrategias de Riesgo Compartido 2009, P.i.M. 19.07.2009, Simon Kucher & Partners Strategy & Marketing Consultants.
7. CVZ Pay-for-Performance Overeenkomst omalizumab (Xolair) voor de behandeling van ernstige astma 2012, (last accessed 21.10.14.). https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2012/1208-pay-for-performance-overeenkomst-omalizumab-xolair-voor-de-behandeling-van-ernstige-astma/Pay-for-Performance+Overeenkomst+omalizumab+%28Xolair%29+voor+de+behandeling+van+ernstige+astma.pdf.
8. CVZ Voorwaardelijk toegelaten geneesmiddelen [List of MEAs Implemented in the Netherlands] 2012, (last accessed 21.10.14.). http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/rubrieken/pakket/pakketbeheer/1210-voorwaardelijk-toegelaten-specialistische-geneesmiddelen/1210-voorwaardelijk-toegelaten-specialistische-geneesmiddelen/Voorwaardelijk+toegelaten+specialistische+geneesmiddelen.pdf.
9. Danzon P.M., Towse A., Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2013, 10.1002/hec.3021.
10. Dupree R., Pasman P. Pakketbeheer specialistische geneesmiddelen 2013, College voor zorgverzekeringen, (last accessed 21.10.14.). https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2013/1312-pakketbeheer-specialistische-geneesmiddelen/Pakketbeheer+specialistische+geneesmiddelen.pdf.
11. Dutch National Health Care Institute Website of the Dutch National Health Care Institute 2014, (last accessed 21.10.14.). http://www.zorginstituutnederland.nl/.
12. EFPIA Improving Patient Access to Innovative Medicines: The Framework in Which Differentiated Pricing May Offer a Solution 2014, European Federation of Pharmaceutical Industries and Associations, Brussels, (last accessed 21.10.14.). http://www.efpia.eu/uploads/Modules/Documents/pac-280214-ai6-a1-differentiated-pricing-position-paper-final.pdf.
13. Ferrario A., Kanavos P. Managed Entry Agreements for Pharmaceuticals: the European Experience 2013, EMiNet, Brussels, Belgium.
14. Gandjour A. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2009, 27:431-432.
15. Garrison L.J., Towse A., Briggs A., de Pouvourville G., Grueger J., Mohr P., et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013, 16:703-719.
16. INAMI-RIZIV Fonds Spécial de Solidarité 2014, (last accessed 21.10.14.). http://www.inami.fgov.be/citizen/fr/medical-cost/SANTH_4_8_1.htm.
17. INAMI-RIZIV Website of the Belgian Institute of National Health Insurance and Disability 2014, (last accessed 21.10.14.). http://www.inami.fgov.be/homefr.htm.
18. Jaroslawski S., Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv. Res. 2011, 11:259.
19. Kalo Z., Annemans L., Garrison L. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev. Pharmacoecon. Outcomes Res. 2013, 13:735-741.
20. Klemp M., Frønsdal K., Facey K., on behalf of the HTAi Policy Forum What principles should govern the use of managed entry agreements?. Int. J. Technol. Assess. Health Care 2011, 27:77-83.
21. Launois R., Ethgen O. Risk-sharing agreements: choice of study design and assessment criteria. Ann. Pharm. Fr. 2013, 71:346-357.
22. Loi sur l'assurance obligatoire soins de santé et indemnités. (14 juillet 1994). (last accessed 21.10.14.). http://www.inami.fgov.be/information/fr/regulation/.
23. McCabe C.J., Stafinski T., Edlin R., Menon D., Behalf Banff A.E.D.S. Access with evidence development schemes a framework for description and evaluation. Pharmacoeconomics 2010, 28:143-152.
24. Morel T., Arickx F., Befrits G., Siviero P., van der Meijden C., Xoxi E., et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J. Rare Dis. 2013, 24:198.
25. Morgan S.G., Thomson P.A., Daw J.R., Friesen M.K. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy 2013, 112:248-254.
26. Nederlandse Zorgautoriteit. BELEIDSREGEL BR/CU-2017: Dure Geneesmiddelen. (last accessed 21.10.14.). http://www.nza.nl/137706/145406/BR-CU-2017.pdf.
27. Nederlandse Zorgautoriteit BELEIDSREGEL BR/CU-2068: Prestaties en tarieven medisch specialistische zorg 2012, Artikel 12: Add-ons, (last accessed 21.10.14.). http://www.nza.nl/137706/145406/430582/BR-CU-2068-Beleidsregel-prestaties-en-tarieven-medisch-specialistische-zorg.pdf.
28. NHS England Quarterly Figures- Including Notifications and Individual Cancer Drug Fund Requests (ICDFRs) 2014, The Cancer Drugs Fund, (last accessed 21.10.14.). http://www.england.nhs.uk/ourwork/pe/cdf/.
29. NHS Northern List of Patient Access Schemes 2014, (last accessed 21.10.14.). http://www.newdevonccg.nhs.uk/information-for-patients/medicines-and-treatments/information-for-healthcare-professionals/nice-guidance/patient-access-schemes/100335.
30. NICE Final Appraisal Determination Bortezomib Monotherapy for Relapsed Multiple Myeloma National Institute for Health and Clinical Excellence 2006, (last accessed 21.10.14.). http://www.nice.org.uk/guidance/ta129/resources/final-appraisal-determination-bortezomib-monotherapy-for-relapsed-multiple-myeloma3.
31. NICE Final Appraisal Determination Bortezomib Monotherapy for Relapsed Multiple Myeloma National Institute for Health and Clinical Excellence 2007, (last accessed 21.10.14.). http://www.nice.org.uk/guidance/ta129/resources/bortezomib-monotherapy-for-relapsed-multiple-myeloma-final-appraisal-determination3.
32. NICE Ranibizumab and Pegaptanib for Age-related Macular Degeneration 2008, National Institute for Health and Clinical Excellence, (last accessed 21.10.14.). http://www.nice.org.uk/guidance/ta155.
33. NICE Appraising Life-extending, End of Life Treatments - Supplementary Advice to the Appraisal Committees 2009, Addendum to Section 6.2.25 of the Guide to the Methods of Technology Appraisal London, (last accessed 21.10.14.). http://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2.
34. NICE Vemurafenib for Treating Locally Advanced or Metastatic BRAF V600 Mutation-positive Malignant Melanoma 2012, NICE technology appraisal guidance 269. London, (last accessed 21.10.14.). http://www.nice.org.uk/guidance/ta269.
35. NICE Website of the National Institute for Health and Clinical Excellence 2014, (last accessed 21.10.14.). http://www.nice.org.uk/.
36. Pickin M., Cooper C.L., Chater T., O'Hagan A., Abrams K.R., Cooper N.J., et al. The multiple Sclerosis risk sharing scheme monitoring study-early results and lessons for the future. BMC Neurol. 2009, 9:1.
37. Ridley D. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005, 23:651-658.
38. Royaume de Belgique Arrêté royal fixant les procédures, délais et conditions en matière d'intervention de l'assurance obligatoire soins de santé et indemnités dans le coÛt des spécialités pharmaceutiques 21 décembre 2001, (last accessed 21.10.14.). http://www.ejustice.just.fgov.be, S.P.F.S.S. Royaume de Belgique (Ed.).
39. Russo P., Mennini F.S., Siviero P.D., Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann. Oncol. 2010, 21:2081-2087.
40. Siviero P. Improving Rational Drug Use through Monitoring Registries LSE Summit on Risk-sharing and Managed Entry Agreements 14 February 2014, London, UK.
41. Stafinski T., McCabe C., Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010, 28:113-142.
42. The Dental and Pharmaceutical Benefits Agency (TLV) Types of Reimbursement 2013, TLV website, (last accessed 21.10.14.). http://www.tlv.se/In-English/medicines-new/pricing-and-reimbursement-of-medicines/types-of-reimbursement/.
43. TLV Besult: Adartel. Stockholm 2006, (last accessed 21.10.14.). http://www.tlv.se/Upload/Beslut_2006/BES_061023_adartrel.pdf.
44. TLV Besult 2012, Adartel, Stockholm, (last accessed 21.10.14.). http://www.tlv.se/Upload/Beslut_2012/Bes121212-adartrel.pdf.
45. TLV Website of the Swedish Dental and Pharmaceutical Benefits Agency 2014, (last accessed 21.10.14.). http://www.tlv.se/.
46. Towse A., Garrison L.P. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010, 28:93-102.
47. UK Department of Health, & ABPI The Pharmaceutical Price Regulation Scheme 2009 2008, 1-98. (last accessed 21.10.14.). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/207462/dh_098498.pdf.
48. Williamson S. AReport into the Uptake of Patient Access Schemes in the NHS 2009, 1-34. Cancer Network Pharmacist Forum, (last accessed 21.10.14.). http://www.bopawebsite.org/contentimages/publications/Report_into_Uptake_of_Patient_Access_Schemes_8_11_09.pdf.
49. Willis M., Persson U., Zoellner Y., Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa(R)) in Sweden. Appl. Health Econ. Health Policy 2010, 8:377-386.
50. Zaric G.S., O'Brien B.J. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. Health Econ. 2005, 14:793-803.
51. Zaric G.S., Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health 2009, 12:838-845.